Recurrent Clostridium Difficile Disease: Epidemiology and Clinical Characteristics

Abstract Objective: To describe the epidemiology, diagnosis, risk factors, patient impact, and treatment strategies for recurrent Clostridium difficile-associated disease (CDAD). Design: Data were collected as part of a blinded, placebo-controlled clinical trial testing a new combination treatment for recurrent CDAD. Retrospective data regarding prior CDAD episodes were collected from interviews and medical-chart review. Prospective data on the current CDAD episode, risk factors, and recurrence rates were collected during a 2-month follow-up. Settings: National referral study. Participants: Patients with recurrent CDAD. Interventions: Treatment with a 10-day course of low-dose (500 mg/d) or high-dose (2 g/d) vancomycin or metronidazole (1 g/d). Results: Recurrent CDAD was found to have a lengthy course involving multiple episodes of diarrhea, abdominal cramping, nausea, and fever. CDAD may recur over several years despite frequent treatment with antibiotics. Recurrence rates were similar regardless of the choice or dose of antibiotic. Recurrent CDAD is not a trivial disease: patients may have multiple episodes (as many as 14), may require hospitalization, and the mean lifetime cost of direct medical care was $10,970 per patient. Fortunately, the disease does not become progressively more severe as the number of episodes increase. Two risk factors predictive for recurrent CDAD were found: increasing age and a decreased quality-of-life score at enrollment. Conclusions: Recurrent CDAD is a persistent disease that may result in prolonged hospital stays, additional medical costs, and rare serious complications.

[1]  D. Pardi,et al.  Clostridium difficile-associated diarrhea and colitis. , 2001, Mayo Clinic proceedings.

[2]  J. Hughes,et al.  Preventing the emergence of antimicrobial resistance. A call for action by clinicians, public health officials, and patients. , 1997, JAMA.

[3]  J. Steiner,et al.  Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians. , 1997, JAMA.

[4]  K. K. Lai,et al.  Clostridium difficile-Associated Diarrhea Epidemiology, Risk Factors, and Infection Control , 1997, Infection Control & Hospital Epidemiology.

[5]  R. Fekety.  Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee. , 1997, The American journal of gastroenterology.

[6]  C. Surawicz,et al.  Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  W. Hueston.  Antibiotics: neither cost effective nor 'cough' effective. , 1997, The Journal of family practice.

[8]  G. Corthier,et al.  Prevalence and pathogenicity of Clostridium difficile in hospitalized patients. A French multicenter study. , 1996, Archives of internal medicine.

[9]  W. Graninger,et al.  Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  D. Piccoli,et al.  Whole-bowel irrigation as an adjunct to the treatment of chronic, relapsing Clostridium difficile colitis. , 1996, Journal of clinical gastroenterology.

[11]  J. Starr,et al.  Increased risk of diarrhoea caused by Clostridium difficile in elderly patients receiving cefotaxime , 1995, BMJ.

[12]  C. Surawicz,et al.  Ciprofloxacin-associated Clostridium difficile disease , 1995, The Lancet.

[13]  J. Biller,et al.  Treatment of recurrent Clostridium difficile colitis with Lactobacillus GG. , 1995, Journal of pediatric gastroenterology and nutrition.

[14]  M. Weinstein,et al.  Bacteremia due to Clostridium difficile: case report and review of extraintestinal C. difficile infections. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  L. Mcfarland,et al.  Isolation of Clostridium difficile at a university hospital: a two-year study. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  C. Surawicz,et al.  A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. , 1994, JAMA.

[17]  S. Nath,et al.  A Sustained Outbreak of Clostridium difficile in a General Hospital: Persistance of a Toxigenic Clone in Four Units , 1994, Infection Control & Hospital Epidemiology.

[18]  D. Gerding,et al.  Ten Years of Prospective Clostridium difficile-Associated Disease Surveillance and Treatment at the Minneapolis VA Medical Center, 1982–1991 , 1994, Infection Control & Hospital Epidemiology.

[19]  J. Bartlett.  Clostridium difficile: history of its role as an enteric pathogen and the current state of knowledge about the organism. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  D. Gerding,et al.  Decrease in Nosocomial Clostridium difficileAssociated Diarrhea by Restricting Clindamycin Use , 1994, Annals of Internal Medicine.

[21]  M. Samore,et al.  Clostridium difficile colonization and diarrhea at a tertiary care hospital. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  C. Beck-Sague,et al.  Epidemic Clostridium difficile- Associated Diarrhea: Role of Second- and Third-Generation Cephalosporins , 1994, Infection Control & Hospital Epidemiology.

[23]  G. Doern,et al.  Laboratory diagnosis of Clostridium difficile-associated gastrointestinal disease: comparison of a monoclonal antibody enzyme immunoassay for toxins A and B with a monoclonal antibody enzyme immunoassay for toxin A only and two cytotoxicity assays , 1992, Journal of Clinical Microbiology.

[24]  K.,et al.  Multicenter evaluation of a new enzyme immunoassay for detection of Clostridium difficile enterotoxin A , 1992, Journal of clinical microbiology.

[25]  L. Rosen,et al.  Clostridium difficile—A common and costly colitis , 1991, Diseases of the colon and rectum.

[26]  R. Zimmerman.  Risk Factors for Clostridium difficile Cytotoxin-Positive Diarrhea After Control for Horizontal Transmission , 1991, Infection Control & Hospital Epidemiology.

[27]  A. Borczyk,et al.  Rapid biochemical test to identify verocytotoxin-positive strains of Escherichia coli serotype O157 , 1990, Journal of clinical microbiology.

[28]  S. Hamilton,et al.  Clostridium difficile invasion and toxin circulation in fatal pediatric pseudomembranous colitis. , 1990, American journal of clinical pathology.

[29]  C. Surawicz,et al.  Risk factors for Clostridium difficile carriage and C. difficile-associated diarrhea in a cohort of hospitalized patients. , 1990, The Journal of infectious diseases.

[30]  T. Walley,et al.  Loperamide related toxic megacolon in Clostridium difficile colitis. , 1990, Postgraduate medical journal.

[31]  S. Borriello,et al.  Quantitative study of antibiotic-induced susceptibility to Clostridium difficile enterocecitis in hamsters , 1990, Antimicrobial Agents and Chemotherapy.

[32]  G. Talbot,et al.  Risk factors for Clostridium difficile toxin-associated diarrhea. , 1990, Infection control and hospital epidemiology.

[33]  R. Ariano,et al.  The role of anion-exchange resins in the treatment of antibiotic-associated pseudomembranous colitis. , 1990, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[34]  E. Ehrenpreis,et al.  Clostridium difficile-associated diarrhea after norfloxacin. , 1990, Journal of clinical gastroenterology.

[35]  I. Nachamkin,et al.  Inappropriate testing for diarrheal diseases in the hospital. , 1990, JAMA.

[36]  L. Peterson,et al.  Prospective, controlled study of vinyl glove use to interrupt Clostridium difficile nosocomial transmission. , 1990, The American journal of medicine.

[37]  C. Surawicz,et al.  Treatment of recurrent Clostridium difficile colitis with vancomycin and Saccharomyces boulardii. , 1989, The American journal of gastroenterology.

[38]  V. Raisys,et al.  Identification of Clostridium difficile in stool specimens by culture-enhanced gas-liquid chromatography , 1989, Journal of clinical microbiology.

[39]  Edward B. Perrin,et al.  The Medical Outcomes Study. An application of methods for monitoring the results of medical care , 1989 .

[40]  J. Rask-Madsen,et al.  BACTERIOTHERAPY FOR CHRONIC RELAPSING CLOSTRIDIUM DIFFICILE DIARRHOEA IN SIX PATIENTS , 1989, The Lancet.

[41]  W. Stamm,et al.  Nosocomial acquisition of Clostridium difficile infection. , 1989, The New England journal of medicine.

[42]  B. Cunha,et al.  Yield of stool cultures, ova and parasite tests, and Clostridium difficile determinations in nosocomial diarrheas. , 1988, American journal of infection control.

[43]  D. Gordon,et al.  Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis. , 1985, The American journal of gastroenterology.

[44]  S. O'farrell,et al.  TYPING SCHEME FOR CLOSTRIDIUM DIFFICILE: ITS APPLICATION IN CLINICAL AND EPIDEMIOLOGICAL STUDIES , 1984, The Lancet.

[45]  D. Gerding,et al.  PROSPECTIVE RANDOMISED TRIAL OF METRONIDAZOLE VERSUS VANCOMYCIN FOR CLOSTRIDIUM-DIFFICILE-ASSOCIATED DIARRHOEA AND COLITIS , 1983, The Lancet.

[46]  R. Roberts,et al.  Relapse of antibiotic associated colitis: endogenous persistence of Clostridium difficile during vancomycin therapy. , 1983, Gut.

[47]  T. Riley,et al.  Diarrhoea associated with Clostridium difficile in a hospital population , 1983, The Medical journal of Australia.

[48]  N. Sullivan,et al.  Investigation of an outbreak of antibiotic-associated colitis by various typing methods , 1982, Journal of clinical microbiology.

[49]  B. Greene,et al.  12 MONTH FOLLOW-UP OF MEBENDAZOLE THERAPY FOR ONCHOCERCIASIS , 1981, The Lancet.

[50]  K. Siu,et al.  VASCULAR COMPRESSION CAUSE OF TRIGEMINAL NEURALGIA , 1980, The Medical journal of Australia.

[51]  J. Bartlett,et al.  Cultures for Clostridium difficile in stools containing a cytotoxin neutralized by Clostridium sordellii antitoxin , 1979, Journal of clinical microbiology.

[52]  R. Slack,et al.  RELAPSE OF PSEUDOMEMBRANOUS COLITIS AFTER VANCOMYCIN THERAPY , 1979, The Lancet.

[53]  R. Slack,et al.  Relapse of pseudomembranous colitis after vancomycin therapy. , 1979, Lancet.

[54]  R. Platt,et al.  Epidemiology of community-acquired Clostridium difficile-associated diarrhea. , 1994, The Journal of infectious diseases.

[55]  S. Yablon,et al.  Clostridium difficile-related disease: evaluation and prevalence among inpatients with diarrhea in two freestanding rehabilitation hospitals. , 1993, Archives of physical medicine and rehabilitation.

[56]  J. Silva,et al.  Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. , 1989, The American journal of medicine.

[57]  B. Aronsson,et al.  Medical implications of nosocomial infection with Clostridium difficile. , 1989, Scandinavian journal of infectious diseases.

[58]  S. Greenfield,et al.  The Medical Outcomes Study , 1989 .

[59]  M. Tvede,et al.  Bacteriotherapy for chronic relapsing Clostridium difficile in six patients , 1989 .

[60]  S. Greenfield,et al.  The Medical Outcomes Study. An application of methods for monitoring the results of medical care. , 1989, JAMA.

[61]  D. Burdon.  Clostridium difficile: The epidemiology and prevention of hospital-acquired infection , 1982, Infection.